These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 24039745

  • 1. Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses.
    Yi G, Lapelosa M, Bradley R, Mariano TM, Dietz DE, Hughes S, Wrin T, Petropoulos C, Gallicchio E, Levy RM, Arnold E, Arnold GF.
    PLoS One; 2013; 8(9):e72205. PubMed ID: 24039745
    [Abstract] [Full Text] [Related]

  • 2. Multiple antigen peptide mimetics containing gp41 membrane-proximal external region elicit broad neutralizing antibodies against human immunodeficiency virus type 1 in guinea pigs.
    Zhang L, Miao L, Gong X, Zhang H, Yang L, Shi Y, Kong W, Jiang C, Shan Y.
    J Pept Sci; 2013 Aug; 19(8):491-8. PubMed ID: 23794478
    [Abstract] [Full Text] [Related]

  • 3. Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.
    Dieltjens T, Heyndrickx L, Willems B, Gray E, Van Nieuwenhove L, Grupping K, Vanham G, Janssens W.
    Retrovirology; 2009 Dec 14; 6():113. PubMed ID: 20003438
    [Abstract] [Full Text] [Related]

  • 4. Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].
    Lapelosa M, Arnold GF, Gallicchio E, Arnold E, Levy RM.
    J Mol Biol; 2010 Apr 02; 397(3):752-66. PubMed ID: 20138057
    [Abstract] [Full Text] [Related]

  • 5. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, Katinger H, Burton DR.
    J Virol; 2005 Jan 02; 79(2):1252-61. PubMed ID: 15613352
    [Abstract] [Full Text] [Related]

  • 6. Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice.
    Yi G, Tu X, Bharaj P, Guo H, Zhang J, Shankar P, Manjunath N.
    Mol Ther; 2015 Oct 02; 23(10):1663-70. PubMed ID: 26061648
    [Abstract] [Full Text] [Related]

  • 7. Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.
    Zhai Y, Zhong Z, Zariffard M, Spear GT, Qiao L.
    Vaccine; 2013 Nov 04; 31(46):5422-9. PubMed ID: 24055348
    [Abstract] [Full Text] [Related]

  • 8. Selection and immune recognition of HIV-1 MPER mimotopes.
    Wieczorek L, Peachman K, Steers N, Schoen J, Rao M, Polonis V, Rao V.
    Virology; 2020 Nov 04; 550():99-108. PubMed ID: 32980676
    [Abstract] [Full Text] [Related]

  • 9. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.
    Arnold GF, Velasco PK, Holmes AK, Wrin T, Geisler SC, Phung P, Tian Y, Resnick DA, Ma X, Mariano TM, Petropoulos CJ, Taylor JW, Katinger H, Arnold E.
    J Virol; 2009 May 04; 83(10):5087-100. PubMed ID: 19279101
    [Abstract] [Full Text] [Related]

  • 10. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA, Moyo T, Schomaker M, Abrahams F, Grau Pujol B, Dorfman JR.
    J Virol; 2015 May 04; 89(10):5264-75. PubMed ID: 25673728
    [Abstract] [Full Text] [Related]

  • 11. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
    Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, Mascola J, Berkower I, Wyatt R.
    Virology; 2008 Mar 30; 373(1):72-84. PubMed ID: 18155743
    [Abstract] [Full Text] [Related]

  • 12. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.
    Ye L, Wen Z, Dong K, Wang X, Bu Z, Zhang H, Compans RW, Yang C.
    PLoS One; 2011 Mar 30; 6(5):e14813. PubMed ID: 21625584
    [Abstract] [Full Text] [Related]

  • 13. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
    Li D, Liu J, Zhang L, Xu T, Chen J, Wang L, Zhao Q.
    Virol Sin; 2015 Dec 30; 30(6):449-56. PubMed ID: 26715302
    [Abstract] [Full Text] [Related]

  • 14. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine.
    Wahome N, Pfeiffer T, Ambiel I, Yang Y, Keppler OT, Bosch V, Burkhard P.
    Chem Biol Drug Des; 2012 Sep 30; 80(3):349-57. PubMed ID: 22650354
    [Abstract] [Full Text] [Related]

  • 15. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane.
    Montero M, Gulzar N, Klaric KA, Donald JE, Lepik C, Wu S, Tsai S, Julien JP, Hessell AJ, Wang S, Lu S, Burton DR, Pai EF, Degrado WF, Scott JK.
    J Virol; 2012 Mar 30; 86(6):2930-41. PubMed ID: 22238313
    [Abstract] [Full Text] [Related]

  • 16. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.
    Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC, Michael NL, Polonis VR, Alving CR.
    AIDS; 2009 Oct 23; 23(16):2069-77. PubMed ID: 19710597
    [Abstract] [Full Text] [Related]

  • 17. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution.
    Shen X, Dennison SM, Liu P, Gao F, Jaeger F, Montefiori DC, Verkoczy L, Haynes BF, Alam SM, Tomaras GD.
    Proc Natl Acad Sci U S A; 2010 Mar 30; 107(13):5972-7. PubMed ID: 20231447
    [Abstract] [Full Text] [Related]

  • 18. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
    Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, Hessell A, Wilson IA, Binley JM, Dawson PE, Burton DR, Zwick MB.
    J Virol; 2007 Apr 30; 81(8):4033-43. PubMed ID: 17287272
    [Abstract] [Full Text] [Related]

  • 19. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes.
    Lapelosa M, Gallicchio E, Arnold GF, Arnold E, Levy RM.
    J Mol Biol; 2009 Jan 16; 385(2):675-91. PubMed ID: 19026659
    [Abstract] [Full Text] [Related]

  • 20. Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.
    Smith AD, Geisler SC, Chen AA, Resnick DA, Roy BM, Lewi PJ, Arnold E, Arnold GF.
    J Virol; 1998 Jan 16; 72(1):651-9. PubMed ID: 9420270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.